These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17593621)

  • 61. Molecular mechanisms in signal transduction: new targets for the therapy of gynecologic malignancies.
    Gabriel B; Fischer DC; Kieback DG
    Onkologie; 2002 Jun; 25(3):240-7. PubMed ID: 12119458
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Role of anti-Her-2 therapy in bladder carcinoma.
    Marín AP; Arranz EE; Sánchez AR; Auñón PZ; Barón MG
    J Cancer Res Clin Oncol; 2010 Dec; 136(12):1915-20. PubMed ID: 20213094
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Renal toxicity of anticancer agents targeting HER2 and EGFR.
    Cosmai L; Gallieni M; Porta C
    J Nephrol; 2015 Dec; 28(6):647-57. PubMed ID: 26341657
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Role of predictive pathology in oncology--example of new therapies targeting EGFR].
    Hartmann A
    Verh Dtsch Ges Pathol; 2006; 90():128-35. PubMed ID: 17867589
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Dual/pan-HER tyrosine kinase inhibitors: focus in breast cancer.
    Albanell J
    Adv Exp Med Biol; 2006; 587():329-40. PubMed ID: 17163175
    [No Abstract]   [Full Text] [Related]  

  • 66. [Anti-HER2 antibody and small-molecule tyrosine kinase inhibitor therapy targeting EGFR signal pathway].
    Yamashiro H; Toi M
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1067-71. PubMed ID: 19620793
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer.
    Esteva FJ
    Oncologist; 2004; 9 Suppl 3():4-9. PubMed ID: 15163841
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer.
    Ahn D; Walden D; Bekaii-Saab T
    Expert Opin Investig Drugs; 2022 May; 31(5):437-441. PubMed ID: 35289234
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Targeted treatment of advanced and metastaticbreast cancer with lapatinib.
    Corkery B; O'Donovan N; Crown J
    Onco Targets Ther; 2008 Sep; 1():21-34. PubMed ID: 21127749
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Developments in chemotherapy of breast cancer.
    Hortobagyi GN
    Cancer; 2000 Jun; 88(12 Suppl):3073-9. PubMed ID: 10898354
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Targeted therapy of breast cancer.
    Longo R; Torino F; Gasparini G
    Curr Pharm Des; 2007; 13(5):497-517. PubMed ID: 17348846
    [TBL] [Abstract][Full Text] [Related]  

  • 72. HER-2 as a Prognostic, Predictive, and Therapeutic Target in Breast Cancer.
    Perez EA
    Cancer Control; 1999 May; 6(3):233-240. PubMed ID: 10758552
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Progression of HER-2 lowly expressed breast cancer and the related anti-tumor drugs].
    Yuan P; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2021 Sep; 43(9):901-905. PubMed ID: 34530570
    [TBL] [Abstract][Full Text] [Related]  

  • 74. HER-2-directed, small-molecule antagonists.
    Arkin M; Moasser MM
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1264-76. PubMed ID: 19037833
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tyrosine Kinase Inhibitors for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Is Personalizing Therapy Within Reach?
    Chien AJ; Rugo HS
    J Clin Oncol; 2017 Sep; 35(27):3089-3091. PubMed ID: 28783451
    [No Abstract]   [Full Text] [Related]  

  • 76. [Consensus on clinical diagnosis and treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (2022 edition)].
    ;
    Zhonghua Zhong Liu Za Zhi; 2022 Dec; 44(12):1288-1295. PubMed ID: 36575781
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The paradoxical functions of EGFR during breast cancer progression.
    Ali R; Wendt MK
    Signal Transduct Target Ther; 2017; 2():16042-. PubMed ID: 28435746
    [TBL] [Abstract][Full Text] [Related]  

  • 78. HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment.
    Sitia L; Sevieri M; Signati L; Bonizzi A; Chesi A; Mainini F; Corsi F; Mazzucchelli S
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626028
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antibody-based imaging of HER-2: moving into the clinic.
    Wang RE; Zhang Y; Tian L; Cai W; Cai J
    Curr Mol Med; 2013 Dec; 13(10):1523-37. PubMed ID: 24206138
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer.
    Flynn JF; Wong C; Wu JM
    J Oncol; 2009; 2009():526963. PubMed ID: 19390622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.